scholarly journals Bone marrow participates in the biosynthesis of human transcobalamin II

Blood ◽  
1980 ◽  
Vol 56 (3) ◽  
pp. 560-563 ◽  
Author(s):  
M Frater-Schroder ◽  
C Nissen ◽  
J Gmur ◽  
L Kierat ◽  
WH Hitzig
Keyword(s):  
Bone Marrow ◽  
Vitamin B12 ◽  
Serum Protein ◽  
Marrow Transplantation ◽  
Total Activity ◽  
Genetic Patterns ◽  
Donor Type ◽  
Before And After ◽  
Bone Marrow Derived Cells ◽  
Transcobalamin Ii

Abstract Studies concerning the site of synthesis of the vitamin B12 binding serum protein, transcobalamin II, have been done in various mammalian animals. The actual site of biosynthesis in man has not yet been defined. The finding that bone marrow derived cells release apo- transcobalamin II in the mouse led us to examine the genetic patterns of transcobalamin II in man, both before and after marrow transplantation. A gradual but incomplete transformation of the recipient's transcobalamin II type into donor's type, corresponding to 75% or less of the total activity, was registered in 4 cases. Surprisingly, persistent host-type TC II, in spite of different donor type, was observed in 4 further marrow recipients. We conclude that hematopoietic cells transferred with the transplanted marrow participate in the biosynthesis of human transcobalamin II.

scholarly journals Bone marrow participates in the biosynthesis of human transcobalamin II

Blood ◽  
1980 ◽  
Vol 56 (3) ◽  
pp. 560-563
Author(s):  
M Frater-Schroder ◽  
C Nissen ◽  
J Gmur ◽  
L Kierat ◽  
WH Hitzig
Keyword(s):  
Bone Marrow ◽  
Vitamin B12 ◽  
Serum Protein ◽  
Marrow Transplantation ◽  
Total Activity ◽  
Genetic Patterns ◽  
Donor Type ◽  
Before And After ◽  
Bone Marrow Derived Cells ◽  
Transcobalamin Ii

Studies concerning the site of synthesis of the vitamin B12 binding serum protein, transcobalamin II, have been done in various mammalian animals. The actual site of biosynthesis in man has not yet been defined. The finding that bone marrow derived cells release apo- transcobalamin II in the mouse led us to examine the genetic patterns of transcobalamin II in man, both before and after marrow transplantation. A gradual but incomplete transformation of the recipient's transcobalamin II type into donor's type, corresponding to 75% or less of the total activity, was registered in 4 cases. Surprisingly, persistent host-type TC II, in spite of different donor type, was observed in 4 further marrow recipients. We conclude that hematopoietic cells transferred with the transplanted marrow participate in the biosynthesis of human transcobalamin II.

Renal tubular regeneration by bone marrow—derived cells in a girl after bone marrow transplantation

2003 ◽  
Vol 42 (5) ◽  
pp. e20.1-e20.3 ◽  
Author(s):  
Masashi Nishida ◽  
Hidekazu Kawakatsu ◽  
Isao Shiraishi ◽  
Shin-ichiro Fujimoto ◽  
Takahiro Gotoh ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Bone Marrow Transplantation ◽  
Marrow Transplantation ◽  
Bone Marrow Derived Cells ◽  
Renal Tubular

scholarly journals Cryopreserved ovarian cortex from patients with leukemia in complete remission contains no apparent viable malignant cells

Blood ◽  
2012 ◽  
Vol 120 (22) ◽  
pp. 4311-4316 ◽  
Author(s):  
Tine Greve ◽  
Erik Clasen-Linde ◽  
Morten T. Andersen ◽  
Mette K. Andersen ◽  
Stine D. Sørensen ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Bone Marrow Transplantation ◽  
Complete Remission ◽  
Quantitative Pcr ◽  
Marrow Transplantation ◽  
Ovarian Tissue ◽  
Malignant Cells ◽  
Ovarian Cortex ◽  
Before And After ◽  
Histology And Immunohistochemistry

Abstract Some women suffering from leukemia require bone marrow transplantation to be cured. Bone marrow transplantation is associated with a high risk of sterility, and some patients are offered fertility preservation by cryopreservation of the ovarian cortex. Transplantation of the ovarian cortex to women cured of leukemia who became menopausal is currently not performed because of the risk of introducing the disease. In this study, individual pieces of ovarian cortex intended for reimplantation from 25 patients with leukemia were transplanted to each of 25 nude mice for 20 weeks. The ovarian cortex was examined before and after transplantation by histology and immunohistochemistry, and RT–quantitative PCR (in the 7 patients with a known marker). Seventeen patients had the ovarian cortex retrieved when they were in complete remission. Before transplantation, 4 of 7 pieces (2 from patients in complete remission) of ovarian cortex had a positive RT–quantitative PCR. After transplantation, none of the mice revealed any sign of disease, neither in the pieces of ovarian cortex transplanted nor in any of the murine organs evaluated. Thus, the ovaries from patients in complete remission do not appear to contain viable malignant cells contrasting ovarian tissue retrieved before treatment.

scholarly journals Phlebotomy to Reduce Iron Overload in Patients Cured of Thalassemia by Bone Marrow Transplantation

Blood ◽  
1997 ◽  
Vol 90 (3) ◽  
pp. 994-998 ◽  
Author(s):  
Emanuele Angelucci ◽  
Pietro Muretto ◽  
Guido Lucarelli ◽  
Marta Ripalti ◽  
Donatella Baronciani ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Bone Marrow Transplantation ◽  
Iron Overload ◽  
Marrow Transplantation ◽  
Iron Concentration ◽  
Transferrin Saturation ◽  
Dry Weight ◽  
Liver Iron ◽  
Before And After ◽  
Upper Level

In thalassemia after successful bone marrow transplantation (BMT), iron overload remains an important cause of morbidity. After BMT, patients have normal erythropoiesis capable of producing a hyperplastic response to phlebotomy so that this procedure can be contemplated as a method of mobilizing iron from overloaded tissues. A phlebotomy program (6 mL/kg blood withdrawal at 14-day intervals) was proposed to 48 patients with prolonged follow-up (range, 2 to 7 years) after BMT. Seven patients were not submitted to the program (five because of refusal and two because of reversible side effects). The remaining 41 patients (mean age, 16 ± 2.9 years) were treated for a mean period of 35 ± 18 months. All were evaluated before and after 3 ± 0.6 years of followup. Values are expressed as mean ± standard deviation (SD) or as median with a range (25 to 75 percentile). Serum ferritin decreased from 2,587 (2,129 to 4,817) to 417 (210 to 982) μg/L (P < .0001), total transferrin increased from 2.34 ± 0.37 to 2.7 ± 0.58 g/L (P = .0001), transferrin saturation decreased from 90% ± 14% to 50% ± 29% (P < .0001). Liver iron concentration evaluated on liver biopsy specimens decreased from 20.8 (15.5 to 28.1) to 4.2 (1.6 to 14.6) mg/g dry weight (P < .0001). Aspartate transaminase decreased from 2.7 ± 2 to 1.1 ± 0.6 (P < .0001) and alanine transaminase from 5.2 ± 3.4 to 1.7 ± 1.2 (P < .0001) times the upper level of normality. The Knodell score for liver histological activity decreased from 6.9 ± 3 to 4.9 ± 2.8 (P < .0001). These data indicate that phlebotomy is safe, efficient, and widely applicable to ex-thalassemics after BMT.

scholarly journals Evidence for engraftment of donor-type multipotent CD34+ cells in a patient with selective T-lymphocyte reconstitution after bone marrow transplantation for B-SCID

Blood ◽  
1994 ◽  
Vol 84 (10) ◽  
pp. 3584-3589 ◽  
Author(s):  
GE Tjonnfjord ◽  
R Steen ◽  
OP Veiby ◽  
W Friedrich ◽  
T Egeland
Keyword(s):  
Bone Marrow ◽  
Bone Marrow Transplantation ◽  
T Lymphocyte ◽  
Marrow Transplantation ◽  
B Lymphocyte ◽  
B Lymphopoiesis ◽  
Type B ◽  
Cd34 Cells ◽  
Donor Type

Severe combined immunodeficiencies (SCID), a heterogeneous group of disorders of infancy, are fatal without treatment directed at immunologic reconstitution. Allogeneic bone marrow transplantation (BMT), which is such a treatment presents some unique features in SCID, especially when T-lymphocyte-depleted HLA haploidentical allografts are used. Donor-type T lymphopoiesis, less often B lymphopoiesis, develops, whereas myelopoiesis remains the recipient-type. Little is known about the engrafting cells in this peculiar lymphohematopoietic chimerism and the pathophysiology of the frequent failure of B-lymphocyte reconstitution. To address these issues, we purified CD34+ BM cells from a patient with selective T-lymphocyte reconstitution after HLA haploidentical BMT for B-SCID. Phenotypic analysis of CD34+ cells was performed by flow cytometry, and functional studies of donor- and recipient-type CD34+ cells were performed in vitro. Donor-type CD34+ cells, constituting approximately 2% of the CD34+ cells, were detected; both CD34+ HLA-DR- cells and CD34+ cells coexpressing B-(CD10 and CD19) and T-(CD2 and CD7) lymphocyte-associated cell surface molecules. Donor- type CD34+ cells coexpressing myeloid-associated molecules (CD13, CD14, CD15, and CD33) were undetectable. However, donor-type CD34+ myeloid progenitors could be shown in functional assays. Recipient-type CD34+ cells coexpressing B- and T-lymphocyte- as well as myeloid-associated molecules were detected, but recipient-type CD34+ cells could not be driven into T-lymphocyte differentiation in vitro. These findings provide evidence for engraftment of multipotent stem cells in our patient with B-SCID. Furthermore, the failure of B-lymphocyte reconstitution cannot be explained by lack of donor-type B-lymphocyte progenitors. Donor-type B lymphopoiesis and myelopoiesis are prevented by an unidentified mechanism.

scholarly journals Evidence for engraftment of donor-type multipotent CD34+ cells in a patient with selective T-lymphocyte reconstitution after bone marrow transplantation for B-SCID

Blood ◽  
1994 ◽  
Vol 84 (10) ◽  
pp. 3584-3589 ◽  
Author(s):  
GE Tjonnfjord ◽  
R Steen ◽  
OP Veiby ◽  
W Friedrich ◽  
T Egeland
Keyword(s):  
Bone Marrow ◽  
Bone Marrow Transplantation ◽  
T Lymphocyte ◽  
Marrow Transplantation ◽  
B Lymphocyte ◽  
B Lymphopoiesis ◽  
Type B ◽  
Cd34 Cells ◽  
Donor Type

Abstract Severe combined immunodeficiencies (SCID), a heterogeneous group of disorders of infancy, are fatal without treatment directed at immunologic reconstitution. Allogeneic bone marrow transplantation (BMT), which is such a treatment presents some unique features in SCID, especially when T-lymphocyte-depleted HLA haploidentical allografts are used. Donor-type T lymphopoiesis, less often B lymphopoiesis, develops, whereas myelopoiesis remains the recipient-type. Little is known about the engrafting cells in this peculiar lymphohematopoietic chimerism and the pathophysiology of the frequent failure of B-lymphocyte reconstitution. To address these issues, we purified CD34+ BM cells from a patient with selective T-lymphocyte reconstitution after HLA haploidentical BMT for B-SCID. Phenotypic analysis of CD34+ cells was performed by flow cytometry, and functional studies of donor- and recipient-type CD34+ cells were performed in vitro. Donor-type CD34+ cells, constituting approximately 2% of the CD34+ cells, were detected; both CD34+ HLA-DR- cells and CD34+ cells coexpressing B-(CD10 and CD19) and T-(CD2 and CD7) lymphocyte-associated cell surface molecules. Donor- type CD34+ cells coexpressing myeloid-associated molecules (CD13, CD14, CD15, and CD33) were undetectable. However, donor-type CD34+ myeloid progenitors could be shown in functional assays. Recipient-type CD34+ cells coexpressing B- and T-lymphocyte- as well as myeloid-associated molecules were detected, but recipient-type CD34+ cells could not be driven into T-lymphocyte differentiation in vitro. These findings provide evidence for engraftment of multipotent stem cells in our patient with B-SCID. Furthermore, the failure of B-lymphocyte reconstitution cannot be explained by lack of donor-type B-lymphocyte progenitors. Donor-type B lymphopoiesis and myelopoiesis are prevented by an unidentified mechanism.

Sign in / Sign up

Export Citation Format

Share Document